ESMO Open

Addition of Tucatinib to Trastuzumab/Pertuzumab After Local Therapy for Isolated icPD in HER2+mBC: Primary Results of the Ph2 BRIDGET Trial in @ESMO_Open presented at #ESMO2026. Median icPFS not reached (mFUP 19.6 months), 46/47 pts alive @ data cut-off. esmoopen.com/article/S2059-…

Ultra-sensitive MRD Assessment in Long-term Complete Responders to Anti-HER2 Therapy in HER2+ mBC: Initial Results from HER2-CR Study in @ESMO_Open presented at #ESMO2026. Most LTR remained ctDNA-; persistent ctDNA+ associated with subsequent PD. esmoopen.com/article/S2059-…

Trastuzumab deruxtecan in patients with desmoplastic small round cell tumors (DSRCT): a retrospective analysis from the French Sarcoma Group in @ESMO_Open presented at #ESMO2026. Substantial activity (10/12,ORR 83%) across HER2 expression. esmoopen.com/article/S2059-…

Liquid biopsy-guided molecular hyperselection for anti-EGFR rechallenge therapy in refractory metastatic colorectal cancer: a pooled analysis of 4 trials in @ESMO_Open presented at #ESMO26. LB-based hyperselection of pts leads to better PFS & OS. esmoopen.com/article/S2059-…

When OS Is Not Enough: The Emerging Need for Context-Sensitive Endpoint Frameworks in Oncology in @ESMO_Open presented at #ESMO2026. Context-sensitive frameworks are needed when OS is immature/confounded/not demonstrable with RTC. esmoopen.com/article/S2059-…